Functional and structural efficacy of a novel combinational therapy of aflibercept and timely focal/grid photocoagulation in diabetic macular oedema: do clinical study results compare favourably with a standard‐of‐care treated real‐world population?
Open Access
- 8 June 2022
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 100 (8) , E1624-E1629
Abstract
Purpose: To evaluate treatment efficacy in diabetic macular oedema (DME) comparing a study population receiving combined intravitreal vascular endothelial growth factor (VEGF) inhibition and focal/grid photocoagulation with a matched, real‐world population receiving standard of care treatment.Methods: In an exploratory study, we included 43 eyes from 32 patients from a previously published study as well as 46 eyes from 38 standard‐of‐care patients. The study population had received a loading dose of three monthly aflibercept injections followed by focal/grid photocoagulation and additional aflibercept pro re nata. Principal measurements at 12 months were numbers of intravitreal injections, best corrected visual acuity (BCVA) and central retinal thickness (CRT).Results: At baseline, there were no differences between groups regarding age, sex, body mass index, haemoglobin A1C, systolic pressure or type of diabetes, but the study population had a higher diastolic pressure (81.6 versus 72.1 mmHg, p = 0.03) and a lower duration of diabetes (12.3 versus 23.2 years, p = 0.03). At month 12, patients in the study group had a higher visual acuity (79.6 versus 74.3 ETDRS letters, p = 0.03), despite having received fewer aflibercept injections (4.4 versus 5.9, p < 0.01) with a higher likelihood of having only received the three mandatory injections in the loading phase (39.5% versus 13.0%, p = 0.01).Conclusion: In comparison to a matched, real‐world DME‐population, patients in combined treatment with intravitreal aflibercept and postloading focal/grid photocoagulation obtained a better functional outcome despite having received fewer intravitreal injections. Future randomized studies are needed to evaluate the long‐term efficacy of this combined treatment regimen.Keywords
This publication has 20 references indexed in Scilit:
- Diabetic Retinopathy and Diabetic Macular Edema2015
- The REVEAL StudyOphthalmology, 2015
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaNew England Journal of Medicine, 2015
- Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial ResultsOphthalmology, 2015
- Comparative Evaluation of Combined Navigated Laser Photocoagulation and Intravitreal Ranibizumab in the Treatment of Diabetic Macular EdemaPLOS ONE, 2014
- The RESTORE StudyOphthalmology, 2011
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- Etiology and Treatment of Macular EdemaAmerican Journal of Ophthalmology, 2009
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985